Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a report issued on Thursday. The firm currently has $8.25 price target on the biopharmaceutical company’s stock.

According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company’s pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson’s disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. “

Other research analysts also recently issued research reports about the company. ValuEngine downgraded Minerva Neurosciences from a strong-buy rating to a buy rating in a report on Tuesday, December 18th. BidaskClub downgraded Minerva Neurosciences from a strong-buy rating to a buy rating in a report on Tuesday, November 13th.

Shares of NASDAQ NERV opened at $7.59 on Thursday. Minerva Neurosciences has a 1-year low of $5.00 and a 1-year high of $12.95. The stock has a market cap of $295.81 million, a price-to-earnings ratio of -7.03 and a beta of 1.60.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.07. As a group, equities analysts expect that Minerva Neurosciences will post -1.28 earnings per share for the current year.

In other Minerva Neurosciences news, Director William F. Doyle acquired 6,000 shares of the company’s stock in a transaction dated Tuesday, December 11th. The shares were acquired at an average price of $7.97 per share, for a total transaction of $47,820.00. Following the acquisition, the director now owns 16,611 shares in the company, valued at approximately $132,389.67. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Geoff Race sold 5,999 shares of the stock in a transaction dated Monday, December 17th. The shares were sold at an average price of $7.46, for a total value of $44,752.54. Following the completion of the transaction, the chief financial officer now owns 204,369 shares in the company, valued at approximately $1,524,592.74. The disclosure for this sale can be found here. In the last quarter, insiders bought 10,000 shares of company stock worth $77,220 and sold 16,007 shares worth $120,971. Corporate insiders own 9.60% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC purchased a new position in shares of Minerva Neurosciences in the 2nd quarter valued at about $135,000. Falcon Point Capital LLC boosted its position in shares of Minerva Neurosciences by 28.6% in the 3rd quarter. Falcon Point Capital LLC now owns 27,933 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 6,209 shares during the period. Acadian Asset Management LLC boosted its position in shares of Minerva Neurosciences by 33.6% in the 3rd quarter. Acadian Asset Management LLC now owns 42,822 shares of the biopharmaceutical company’s stock valued at $538,000 after purchasing an additional 10,762 shares during the period. Alpine Woods Capital Investors LLC boosted its position in shares of Minerva Neurosciences by 22.7% in the 3rd quarter. Alpine Woods Capital Investors LLC now owns 61,329 shares of the biopharmaceutical company’s stock valued at $770,000 after purchasing an additional 11,329 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Minerva Neurosciences by 38.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 65,567 shares of the biopharmaceutical company’s stock valued at $541,000 after purchasing an additional 18,267 shares during the period. Institutional investors and hedge funds own 75.09% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Further Reading: Understanding Relative Strength Index

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.